HUT70272A - Recombinant antibodies for human therapy - Google Patents
Recombinant antibodies for human therapyInfo
- Publication number
- HUT70272A HUT70272A HU9400201A HU9400201A HUT70272A HU T70272 A HUT70272 A HU T70272A HU 9400201 A HU9400201 A HU 9400201A HU 9400201 A HU9400201 A HU 9400201A HU T70272 A HUT70272 A HU T70272A
- Authority
- HU
- Hungary
- Prior art keywords
- recombinant antibodies
- human therapy
- therapy
- human
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73506491A | 1991-07-25 | 1991-07-25 | |
US85628192A | 1992-03-23 | 1992-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
HU9400201D0 HU9400201D0 (en) | 1994-05-30 |
HUT70272A true HUT70272A (en) | 1995-09-28 |
Family
ID=27112830
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9400201A HUT70272A (en) | 1991-07-25 | 1992-07-24 | Recombinant antibodies for human therapy |
HU95P/P00595P HU211881A9 (en) | 1991-07-25 | 1995-06-29 | Recombinant antibodies for human therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU95P/P00595P HU211881A9 (en) | 1991-07-25 | 1995-06-29 | Recombinant antibodies for human therapy |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP0605442B1 (hu) |
JP (1) | JP3048640B2 (hu) |
KR (1) | KR0137806B1 (hu) |
AP (1) | AP307A (hu) |
AT (2) | ATE327331T1 (hu) |
AU (1) | AU673499B2 (hu) |
BG (1) | BG62656B1 (hu) |
BR (1) | BR9206313A (hu) |
CA (1) | CA2114015C (hu) |
CZ (1) | CZ289472B6 (hu) |
DE (2) | DE69233011T2 (hu) |
DK (2) | DK1266965T3 (hu) |
ES (2) | ES2265005T3 (hu) |
FI (1) | FI117703B (hu) |
HU (2) | HUT70272A (hu) |
IL (1) | IL102640A0 (hu) |
MY (1) | MY121185A (hu) |
NO (1) | NO318097B1 (hu) |
NZ (1) | NZ243706A (hu) |
OA (1) | OA09879A (hu) |
PT (1) | PT100735B (hu) |
RO (1) | RO116404B1 (hu) |
SK (2) | SK285960B6 (hu) |
WO (1) | WO1993002108A1 (hu) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
ES2199216T3 (es) * | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
ES2151054T3 (es) * | 1994-04-26 | 2000-12-16 | Kanebo Ltd | Farmaco para el tratamiento de la artritis reumatoide. |
WO1996012741A1 (en) * | 1994-10-25 | 1996-05-02 | Glaxo Group Limited | Binding agents to cd23 |
JP2001506122A (ja) * | 1994-12-07 | 2001-05-15 | エフ.ホフマン−ラ ロシュ アーゲー | 免疫抑制作用を有するモノクローナル抗体断片 |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
CA2327505A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
EP1946775A3 (en) | 1998-08-11 | 2008-08-06 | Biogen Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
KR101092132B1 (ko) | 1998-11-09 | 2011-12-12 | 바이오겐 아이덱 인크. | 키메라 항-cd20항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법 |
US7820161B1 (en) | 1999-05-07 | 2010-10-26 | Biogen Idec, Inc. | Treatment of autoimmune diseases |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
AU2001271614B2 (en) * | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
EP1299556A2 (en) * | 2000-07-03 | 2003-04-09 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
AU7025201A (en) | 2000-07-03 | 2002-01-14 | Gala Design Inc | Expression vectors |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
US20050101012A1 (en) | 2001-03-12 | 2005-05-12 | Gerold Schuler | CD4+CD25+ regulatory T cells from human blood |
TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
US8222033B2 (en) | 2002-08-12 | 2012-07-17 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
EP1692174A2 (en) * | 2003-11-07 | 2006-08-23 | Amgen Inc. | Monkey immunoglobulin sequences |
US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
KR100942849B1 (ko) | 2004-03-30 | 2010-02-17 | 글락소 그룹 리미티드 | 면역글로불린 |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
WO2007117264A2 (en) * | 2005-08-03 | 2007-10-18 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
RU2008110058A (ru) * | 2005-08-15 | 2009-09-27 | Арана Терапьютикс Лимитед (Au) | Химерные антитела с областями приматов нового света |
AU2006281980A1 (en) * | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
US20090286962A1 (en) * | 2005-12-20 | 2009-11-19 | Woolven Benjamin P | Chimeric antibodies with part new world primate binding regions |
EA017417B1 (ru) | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ |
WO2008017126A1 (en) | 2006-08-11 | 2008-02-14 | Csl Limited | Treatment of pulmonary disease conditions |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
PL2829551T3 (pl) | 2006-10-19 | 2018-04-30 | Csl Limited | Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13 |
DK2068922T3 (da) | 2006-10-19 | 2012-10-08 | Csl Ltd | Anti-IL-13Ralfa1-antistoffer samt deres anvendelser |
US20090143288A1 (en) | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
JP5588983B2 (ja) | 2008-08-11 | 2014-09-10 | ウェルズ ファーゴ バンク ナショナル アソシエイション | マルチアームポリマーアルカノエートコンジュゲート |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
BR112013013083A2 (pt) | 2010-11-30 | 2016-12-13 | Genentech Inc | métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
DE202012013147U1 (de) * | 2011-10-31 | 2015-01-22 | Jan-Niklas Keltsch | Einhändig bedienbare Verpackung |
CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
CA3049114A1 (en) | 2017-01-04 | 2018-07-12 | Lauren O. Bakaletz | Antibody fragments for the treatment of biofilm-related disorders |
AU2018206552A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
MX2019008989A (es) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. |
AU2017398101A1 (en) | 2017-02-07 | 2019-08-01 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
CA3056088A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
EP3861021A4 (en) | 2018-10-05 | 2022-06-22 | Research Institute at Nationwide Children's Hospital | COMPOSITIONS AND METHODS FOR ENZYMATIC DESTRUCTION OF BACTERIAL BIOFILM |
BR112021023295A2 (pt) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
KR20220032066A (ko) | 2019-07-08 | 2022-03-15 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 생물막을 파괴하기 위한 항체 조성물 |
EP4161574A1 (en) | 2020-06-04 | 2023-04-12 | BioInvent International AB | Improving antibody tolerability associated with intravenous administration |
IL305469A (en) | 2021-03-09 | 2023-10-01 | Bioinvent Int Ab | New combinations of antibodies and their uses |
WO2023161448A1 (en) | 2022-02-24 | 2023-08-31 | Abnomx Bv | Human-like target-binding proteins |
TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2199216T3 (es) * | 1991-07-15 | 2004-02-16 | The Wellcome Foundation Limited | Produccion de anticuerpos. |
-
1992
- 1992-07-24 DK DK02012106T patent/DK1266965T3/da active
- 1992-07-24 WO PCT/US1992/006194 patent/WO1993002108A1/en active IP Right Grant
- 1992-07-24 AT AT02012106T patent/ATE327331T1/de active
- 1992-07-24 NZ NZ243706A patent/NZ243706A/en unknown
- 1992-07-24 IL IL102640A patent/IL102640A0/xx not_active IP Right Cessation
- 1992-07-24 DE DE69233011T patent/DE69233011T2/de not_active Expired - Fee Related
- 1992-07-24 AU AU24255/92A patent/AU673499B2/en not_active Ceased
- 1992-07-24 EP EP92917108A patent/EP0605442B1/en not_active Expired - Lifetime
- 1992-07-24 JP JP5503072A patent/JP3048640B2/ja not_active Expired - Fee Related
- 1992-07-24 BR BR9206313A patent/BR9206313A/pt not_active Application Discontinuation
- 1992-07-24 ES ES02012106T patent/ES2265005T3/es not_active Expired - Lifetime
- 1992-07-24 RO RO94-00095A patent/RO116404B1/ro unknown
- 1992-07-24 KR KR1019940700217A patent/KR0137806B1/ko not_active IP Right Cessation
- 1992-07-24 EP EP02012106A patent/EP1266965B1/en not_active Revoked
- 1992-07-24 CZ CZ1994149A patent/CZ289472B6/cs not_active IP Right Cessation
- 1992-07-24 DK DK92917108T patent/DK0605442T3/da active
- 1992-07-24 SK SK5059-2005A patent/SK285960B6/sk not_active IP Right Cessation
- 1992-07-24 EP EP06010708A patent/EP1715045A3/en not_active Withdrawn
- 1992-07-24 CA CA002114015A patent/CA2114015C/en not_active Expired - Fee Related
- 1992-07-24 HU HU9400201A patent/HUT70272A/hu unknown
- 1992-07-24 DE DE69233628T patent/DE69233628T2/de not_active Revoked
- 1992-07-24 AT AT92917108T patent/ATE237638T1/de not_active IP Right Cessation
- 1992-07-24 ES ES92917108T patent/ES2196002T3/es not_active Expired - Lifetime
- 1992-07-24 SK SK88-94A patent/SK285046B6/sk not_active IP Right Cessation
- 1992-07-25 MY MYPI92001327A patent/MY121185A/en unknown
- 1992-07-27 AP APAP/P/1992/000413A patent/AP307A/en active
- 1992-07-27 PT PT100735A patent/PT100735B/pt not_active IP Right Cessation
-
1994
- 1994-01-21 NO NO19940219A patent/NO318097B1/no not_active IP Right Cessation
- 1994-01-24 BG BG98411A patent/BG62656B1/bg unknown
- 1994-01-24 FI FI940336A patent/FI117703B/fi active IP Right Grant
- 1994-01-24 OA OA60460A patent/OA09879A/en unknown
-
1995
- 1995-06-29 HU HU95P/P00595P patent/HU211881A9/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9400201D0 (en) | Recombinant antibodies for human therapy | |
GB9221654D0 (en) | Recombinant human anti-cytomegalovirus antibodies | |
AP9801209A0 (en) | Recombinant anti-CD4 antibodies for human therapy | |
IL97005A0 (en) | Recombinant human anti-cd18 antibodies | |
EP0438312A3 (en) | Recombinant human anti-cd18 antibodies | |
GB9103454D0 (en) | Therapeutic agents | |
GB9117852D0 (en) | Therapeutic agents | |
GB9104136D0 (en) | Therapeutic agents | |
SG67924A1 (en) | Recombinant antibodies for human therapy | |
GB8917406D0 (en) | Therapeutic aid | |
EP0463571A3 (en) | Recombinant human osteocalcin | |
GB9106568D0 (en) | Recombinant antigen | |
ZA924083B (en) | Therapeutic preparations | |
GB9104937D0 (en) | Therapeutic preparation | |
GB9318287D0 (en) | Protein for therapy | |
EG19704A (en) | Therapeutic agents | |
ZA91346B (en) | Recombinant human anti-cd18 antibodies | |
GB9201133D0 (en) | Therapeutic preparations | |
GB9017548D0 (en) | Therapeutic preparation | |
GB9127354D0 (en) | Agents for therapy | |
GB9222633D0 (en) | Therapeutic agetns | |
GB9100019D0 (en) | Therapeutic agents | |
GB9100648D0 (en) | Therapeutic agents | |
GB9102222D0 (en) | Therapeutic agents | |
GB9102809D0 (en) | Therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |